Komori
Share Issuance and Disposal4596Kubota Pharmaceutical Holdings Co.,Ltd.Pharmaceuticals

Notice of completion of payment of the issuance price for the 41st Series Stock Acquisition Rights (with provisions for adjustment of the exercise price) and the 42nd Series Stock Acquisition Rights issued through a third-party allotment

Payment of the issuance price for the previously approved 41st and 42nd Series Stock Acquisition Rights has been completed. The 41st Series was subscribed for by EVO FUND, and the 42nd Series by Representative Director Kubota Ryo (窪田良).

Worth reading
61In focus
Scored from 3 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
1800000
Japanese yen (total issue price)
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Completion of payment of the issuance price for the 41st Series Stock Acquisition Rights (with provisions for adjustment of the exercise price) and the 42nd Series Stock Acquisition Rights issued through a third-party allotment

Who receives how much

41st Series: 20,000,000 potential common shares; 42nd Series: 20,000,000 potential common shares

EVO FUND20,000,000 potential common shares
Kubota Ryo (窪田良)20,000,000 potential common shares

The height of each bar represents the proportion of shares received by each allottee. The thin line below represents the number of existing shares to which these shares are added.

41st Series: ¥8 per stock acquisition right; 42nd Series: ¥1 per stock acquisition right
Total issue value

41st Series: ¥1,600,000; 42nd Series: ¥200,000; total: ¥1,800,000

Amount of funds to be raised
41st Series: ¥1,201,600,000; 42nd Series: ¥1,200,200,000. Estimated net proceeds: Not disclosed
Terms of the stock acquisition rights
Exercise price
41st Series: initially ¥60. Adjusted every 2 trading days to 100% of the simple average closing price for the 2 consecutive preceding trading days, with a floor of ¥30. 42nd Series: ¥60. No adjustment during the exercise period. Includes a full-ratchet adjustment provision.
Exercise period
41st Series: from 10 November 2026 to 10 November 2028. 42nd Series: from 10 November 2026 to 10 November 2031
Number of Stock Acquisition Rights
41st Series: total issued, 200,000 rights; outstanding unexercised balance: Not disclosed. 42nd Series: total issued, 200,000 rights; outstanding unexercised balance: Not disclosed
Reason for acquisition without consideration
41st Series: If the company determines by resolution of the Board of Directors that acquisition is necessary, the rights may be acquired after 1 month has elapsed from the payment date. All remaining rights will be acquired on 10 November 2028. 42nd Series: All remaining rights will be acquired on 10 November 2031.
Categories and Number of Persons Covered
EVO FUND: 1 entity; Kubota Ryo (窪田良): 1 person
Payment date
9 November 2026
Procedures under the Corporate Code of Conduct
For the 42nd Series, no full-ratchet adjustment will be made if unanimous approval is not obtained from the company's Audit and Supervisory Committee.
Details of issuance or disposal
ItemDetails
Type of issuance or disposalCompletion of payment of the issuance price for the 41st Series Stock Acquisition Rights (with provisions for adjustment of the exercise price) and the 42nd Series Stock Acquisition Rights issued through a third-party allotment
Number of shares to be issued or disposed of41st Series: 20,000,000 potential common shares; 42nd Series: 20,000,000 potential common shares
Issue price and disposal price41st Series: ¥8 per stock acquisition right; 42nd Series: ¥1 per stock acquisition right
Total issue value41st Series: ¥1,600,000; 42nd Series: ¥200,000; total: ¥1,800,000
Amount of funds to be raised41st Series: ¥1,201,600,000; 42nd Series: ¥1,200,200,000. Estimated net proceeds: Not disclosed
Payment date9 November 2026
Intended allotteeName EVO FUND / Number of Shares 20,000,000 potential common shares, Name Kubota Ryo (窪田良) / Number of Shares 20,000,000 potential common shares
Exercise price41st Series: initially ¥60. Adjusted every 2 trading days to 100% of the simple average closing price for the 2 consecutive preceding trading days, with a floor of ¥30. 42nd Series: ¥60. No adjustment during the exercise period. Includes a full-ratchet adjustment provision.
Exercise period41st Series: from 10 November 2026 to 10 November 2028. 42nd Series: from 10 November 2026 to 10 November 2031
Number of Stock Acquisition Rights41st Series: total issued, 200,000 rights; outstanding unexercised balance: Not disclosed. 42nd Series: total issued, 200,000 rights; outstanding unexercised balance: Not disclosed
Reason for acquisition without consideration41st Series: If the company determines by resolution of the Board of Directors that acquisition is necessary, the rights may be acquired after 1 month has elapsed from the payment date. All remaining rights will be acquired on 10 November 2028. 42nd Series: All remaining rights will be acquired on 10 November 2031.
Categories and Number of Persons CoveredEVO FUND: 1 entity; Kubota Ryo (窪田良): 1 person
Procedures under the Corporate Code of ConductFor the 42nd Series, no full-ratchet adjustment will be made if unanimous approval is not obtained from the company's Audit and Supervisory Committee.
Items this document does not state (15)
Estimated issuance expensesSpecific use of fundsIntended allottee's holding policyDilution RateTotal number of issued sharesBasis for determining the amount to be paidTransfer restriction periodConditions for lifting transfer restrictionsTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMost recent equity financingMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Because payment of the total issuance price for the stock acquisition rights approved at the Board of Directors meeting held on 23 October 2026 has been completed.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of completion of payment of the issuance price for the 41st Series Stock Acquisition Rights (with provisions for adjustment of the exercise price) and the 42nd Series Stock Acquisition Rights issued through a third-party allotment | Kubota Pharmaceutical Holdings Co.,Ltd. (4596) timely disclosure | Komori